Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 5/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.41 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | CDC25C | P30307 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068833 | 0.86 | POLB (0.49) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL12297707 | 0.82 | POLB (0.48) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL4891140 | 0.82 | BRD4 (0.50) | POLBALDH1A1GAABMPR1BBMPR1A | |
| SCHEMBL26932019 | 0.81 | POLB (0.47) | POLBPKMTRIM24ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL30630728 | 0.79 | POLB (0.46) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL17229317 | 0.78 | ACVRL1 (0.46) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL20424943 | 0.77 | ALDH1A1 (0.46) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL29036477 | 0.77 | PKM (0.55) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL13656404 | 0.76 | POLB (0.42) | POLBPKMTRIM24ALDH1A1GAA | |
| SCHEMBL1925311 | 0.75 | PKM (0.59) | POLBPKMTRIM24ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1558608-A1 | OXINDOLE SUBSTITUTED PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004100957-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | POLB 2107/4885PKM 3173/4885TRIM24 1896/4885 |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | POLB 3003/4885PKM 3400/4885TRIM24 3221/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | POLB 1657/4885PKM 2495/4885TRIM24 4429/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | POLB 1965/4885PKM 2928/4885TRIM24 4163/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | POLB 2918/4885PKM 981/4885TRIM24 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.